Literature DB >> 21105756

An assessment of the use of chimpanzees in hepatitis C research past, present and future: 1. Validity of the chimpanzee model.

Jarrod Bailey1.   

Abstract

The USA is the only significant user of chimpanzees in biomedical research in the world, since many countries have banned or limited the practice due to substantial ethical, economic and scientific concerns. Advocates of chimpanzee use cite hepatitis C research as a major reason for its necessity and continuation, in spite of supporting evidence that is scant and often anecdotal. This paper examines the scientific and ethical issues surrounding chimpanzee hepatitis C research, and concludes that claims of the necessity of chimpanzees in historical and future hepatitis C research are exaggerated and unjustifiable, respectively. The chimpanzee model has several major scientific, ethical, economic and practical caveats. It has made a relatively negligible contribution to knowledge of, and tangible progress against, the hepatitis C virus compared to non-chimpanzee research, and must be considered scientifically redundant, given the array of alternative methods of inquiry now available. The continuation of chimpanzee use in hepatitis C research adversely affects scientific progress, as well as chimpanzees and humans in need of treatment. Unfounded claims of its necessity should not discourage changes in public policy regarding the use of chimpanzees in US laboratories.
© 2010 FRAME.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21105756     DOI: 10.1177/026119291003800501

Source DB:  PubMed          Journal:  Altern Lab Anim        ISSN: 0261-1929            Impact factor:   1.303


  3 in total

1.  Hepatitis C virus infection reduces the lifespan of chimpanzees used in biomedical research.

Authors:  Satoshi Hirata; Kristin Havercamp; Yumi Yamanashi; Toshifumi Udono
Journal:  Biol Lett       Date:  2022-08-10       Impact factor: 3.812

2.  Evidence for novel hepaciviruses in rodents.

Authors:  Jan Felix Drexler; Victor Max Corman; Marcel Alexander Müller; Alexander N Lukashev; Anatoly Gmyl; Bruno Coutard; Alexander Adam; Daniel Ritz; Lonneke M Leijten; Debby van Riel; Rene Kallies; Stefan M Klose; Florian Gloza-Rausch; Tabea Binger; Augustina Annan; Yaw Adu-Sarkodie; Samuel Oppong; Mathieu Bourgarel; Daniel Rupp; Bernd Hoffmann; Mathias Schlegel; Beate M Kümmerer; Detlev H Krüger; Jonas Schmidt-Chanasit; Alvaro Aguilar Setién; Veronika M Cottontail; Thiravat Hemachudha; Supaporn Wacharapluesadee; Klaus Osterrieder; Ralf Bartenschlager; Sonja Matthee; Martin Beer; Thijs Kuiken; Chantal Reusken; Eric M Leroy; Rainer G Ulrich; Christian Drosten
Journal:  PLoS Pathog       Date:  2013-06-20       Impact factor: 6.823

3.  Hepatitis C virus infection and related liver disease: the quest for the best animal model.

Authors:  Laurent Mailly; Eric Robinet; Philip Meuleman; Thomas F Baumert; Mirjam B Zeisel
Journal:  Front Microbiol       Date:  2013-07-26       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.